A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone Across All Treatment Lines in Patients with MSI-high or dMMR mCRC By Ogkologos - February 5, 2025 134 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer MOST POPULAR A Vaccine to Treat Non-Hodgkin Lymphoma Advancing in Clinical Trials May 7, 2019 Worries About Medical Bills May Worsen Health Outcomes After Cancer Diagnosis March 13, 2021 Using Immunotherapy to Treat Advanced Melanoma and Advanced Non-Small Cell Lung... March 14, 2022 New lung cancer treatment combo approved on NHS in England January 12, 2022 Load more HOT NEWS Why People With Cancer Need to Be Taking Care of Their... Mutational Patterns Drive Metastatic Aggressiveness of Appendiceal Adenocarcinomas Ventana HER2 Dual ISH Assay, A New Diagnostic Tool From Roche,... Mom Finding Out Baby’s Gender Uncovers Rare Condition When Doctors See...
